Category Specific RSS



    • Articles
    • Views
    AUTHOR

    Samantha Freidin

    Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.

Author's Posts

  • Paradigm’s study could give options to those with this rare incurable disease

    Clinical stage biopharmaceutical company Paradigm Biopharmaceuticals (ASX: PAR) has been given the green light to go ahead with a Phase 2 study of their flagship drug, pentosan polysulfate sodium (PPS) in patients with Mucopolysaccharidosis type VI (MPS VI). A big word to digest on a Friday morning, I know. The inherited disease is caused by

    Read More
    Public
  • Move over x-ray: 4D Medical’s respiratory scanning tech could be the new standard in imaging

    Invented in 1895 and becoming the standard in the early 1900s, the x-ray has long been the backbone of many medical diagnoses. The relatively unchanged technology has been commonplace for decades, but medtech company 4D Medical (ASX: 4DX) is rethinking the way we diagnose respiratory issues with their proprietary XV Technology™ and Permetium preclinical scanner. 

    Read More
    Public
  • Spray-on skin revenue exceeds initial forecasts

    The inventors of “spray-on skin”, Avita Medical (ASX: AVH) have today released their financial results for the fiscal fourth quarter with the Company reporting strong revenue. The Company was founded to develop and commercialise the RECELL “spray-on skin” product, invented in Perth by Professor Fiona Wood. Professor Wood is a world renowned surgeon and researcher

    Read More
    Public
  • Goop might have been right…

    The keto diet is proving to be more than just another “It” diet touted by Goop with interesting research showing that it may have a place in cancer treatment. Eating a keto diet puts the body in a state of ketogenesis where instead of running off glucose based energy, the body is fueled by fats

    Read More
    Public
  • IPO Watch: Gefen Technologies to list on ASX with digital marketing platform for agents

    With initial plans to list in the Australian market last year furloughed by the pandemic, Israeli tech company Gefen Technologies is finally joining the dozen Israeli companies on the ASX, having closed their $25 million IPO at the end of last month. Israel is renowned for their ‘start up culture’, especially in tech, having produced

    Read More
    Public
  • How Noxopharm is overhauling the way we approach cancer treatment

    Traditional chemotherapy and radiotherapy have long been the standard of care for cancer treatment, but it’s no secret that there are numerous, debilitating side effects to a patient’s physical and mental health. Both are oftentimes ineffective with several cancers exhibiting poor responsiveness to traditional treatment.  Clinical-stage drug development company Noxopharm (ASX: NOX) is addressing this

    Read More
    Public
  • Epsilon to provide medicinal cannabis for clinical study in children

    A hot topic in medical research at the moment, medicinal cannabis studies are being carried out for seemingly any and all ailments. One such trial being run by the Murdoch Children’s Research Institute (MCRI) is extending efficacy studies of cannabidiol medicine to children with intellectual disability that exhibit severe behavioural problems. To facilitate these studies,

    Read More
    Public
  • Pharmaxis Investor Briefing – Cancer Treatment Clinical Trials

    On 4 June, 2021, Pharmaxis (ASX: PXS) hosted an investor briefing with CEO Gary Phillips to update investors on recent achievements and future plans, plus a Q&A with attendees. Topics discussed in the briefing and question time included: Clinical trial stage progress and timelines; Anticipated news flow for 2021-2022; Commercial opportunities being explored in collaborationRead More
    Public
  • Mad Paws to acquire Waggly Club, our office dog approves

    Feeding our office dog and many other pups Australia wide with their subscription meal service, Dinner Bowl, it’s safe to say Mad Paws (ASX: MPA) understands the subscription market. The Company has today announced the acquisition of one of Australia’s largest dog treats and toys subscription business, Waggly Club. Since its inception when founded by

    Read More
    Public
  • Strong sales continue for ZOLEO satellite messaging device

    Beam Communications (ASX: BCC) is enjoying the continued success of their satellite messaging device ZOLEO and has announced that they have received new orders for 22,000 of them. Sales have remained strong since ZOLEO’s launch in December 2019 with the device filling a previously unmet need for an affordable, compact and clever satellite messaging device.

    Read More
    Public
  • Could Dimerix be first to market with their innovative kidney disease drug?

    Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) has today announced that their current Phase 3 drug for kidney disease has been awarded an Innovation Passport and the Innovative Licensing and Access Pathway (ILAP). The designation is awarded by the UK Medicines and Healthcare products Regulatory Agency and is designed to accelerate development of promising medicines to

    Read More
    Public
  • Openn Negotiation proptech IPO to bring transparency to real estate market

    The slimy sales tactics of prickly real estate agents may be in need of review with Australian property technology company Openn Negotiation set to debut on the ASX on Friday, 11 June.  A “proptech” company, Openn uses technology that aims to provide the best possible property sales outcomes for the seller, buyer and real estate

    Read More
    Public
  • Smart pain assessment app now used by more than half of Australia’s residential aged care providers

    Intelligent pain assessment company Painchek (ASX: PCK) is eager to become the new standard of care in aged care settings, today announcing that licensed agreements for their platform’s use now encompass 60% of Australian aged care providers. PainChek’s mobile based pain assessment tool uses AI and facial recognition software to objectively automate and quantify pain

    Read More
    Public
  • PharmAust receives ethics approval just in time for Big Freeze

    There is nothing fun about plunging into freezing cold ice water during a cold Melbourne winter. However, each year, bold celebrities participate in the annual ‘Big Freeze’ at the Melbourne Cricket Ground before the Melbourne vs Collingwood AFL clash on the Queen’s Birthday weekend.  The event, run by FightMND is designed to raise funds for

    Read More
    Public
  • ‘Working from home’ here to stay as productive Australians focus on wellbeing

    Among the many unknowns to emerge from the pandemic, the working from home phenomenon has plagued executive management but questions as to whether it would become the norm have been categorically answered with a resounding YES. Surveys have shown that working from home improves productivity and contributes to a better work life balance. Not having

    Read More
    Public
  • Genetic Technologies launches AI-based COVID Risk Test

    Personalised medicine is quickly becoming the new standard of healthcare thanks to the ease of genetic testing and technological advancements. Genetic Technologies (ASX: GTG) is pioneering a preventative, individualised approach to the COVID-19 pandemic through their experience in genomics and AI driven preventative health. Having already created genetic testing kits to predict breast and colorectal

    Read More
    Public
  • Avecho Biotechnology expands their proprietary drug delivery system to livestock

    Necessity is the mother of all invention, and seeing an opportunity, Avecho Biotechnology (ASX: AVE) has set about innovating a new livestock feed additive. The development of a new feed additive for animal use comes in anticipation of the European Union’s impending ban on livestock feeds with zinc oxide levels above a certain level. Zinc

    Read More
    Public
  • ZOLEO’s location tracking eliminates the need to drink piss, Bear Grylls thrilled

    Clunky satellite phones reminiscent of the bulky Nokia’s you’d carry around in the 90’s could soon become a thing of the past with Beam Communications’ (ASX: BCC) sexier tech offering. Beam’s joint venture company ZOLEO is well and truly changing the satellite phone game for adventurers the world over. The ZOLEO Satellite Communicator is an

    Read More
    Public
  • Food prototype success for Wide Open Agriculture’s plant-based proteins

    As someone with a penchant for oat milk lattes, Wide Open Agriculture’s (ASX: WOA) announcement today was music to my ears.  The regenerative food and agriculture company develops and distributes food products with a focus on conscious consumers.  They have today announced the results of a three month intensive research exercise conducted at Curtin University

    Read More
    Public
  • From A to B: Traffic Technologies is improving road safety in Victoria

    The removal of level crossings across Victoria has been a welcome change for Melbournians who have been reaping the benefits of smoother flowing traffic and less of that annoying, incessant ‘ding ding ding ding’ that we all despise. So far the Victorian Government’s “Big Build” program has seen the removal of 46 of 75 level

    Read More
    Public
  • 🎵 The knee bone’s connected to the… collagen rope device (?!)

    Regenerative medicine company Orthocell (ASX: OCC) has been granted patents from both China and Hong Kong for their proprietary novel CelGro® collagen rope device.  The addition of these two new patents means that the device is now patented across five jurisdictions including the US and Australia. The IP protection is integral to Orthocell’s commercialisation plans. 

    Read More
    Public
  • Investing 101: Five top tips for new investors

    We know that the share market can be confusing to navigate, and investing for the first time can be daunting. Before you start investing it’s important to understand some of the fundamentals of how the share market works as well as your preferences as an investor. We have put together our 5 top tips for

    Read More
    Public
  • Q&A: Paradigm to answer FDA questions to achieve Investigational New Drug status

    The commercialisation of osteoarthritis treatment ZILOSUL® has hit a hiccup in the United States with the US Food and Drug Administration (FDA) raising fresh questions to late-stage drug development company, Paradigm Biopharmaceuticals (ASX: PAR). The FDA response related to Paradigm’s application for Investigational New Drug status to be granted for their focus compound, Pentosan Polysulfate

    Read More
    Public
  • Zip expands to Europe and Middle East with further strategic acquisitions

    Zip Co’s (ASX: Z1P) global expansion plans are being realised with the Company today announcing the next steps for their push into overseas markets through the outright acquisitions of European BNPL provider Twisto Payments, and UAE-based BNPL leader Spotii Holdings. The move aligns with Zip’s strategic acquisitions plan. Both companies have been integrated into Zip’s

    Read More
    Public
  • Plenty of fish in the sea: Ridley to sell Tasmanian aquaculture facility

    Australia’s largest commercial provider of animal nutrition solutions, Ridley Corporation (ASX: RIC) has today announced the sale of their Tasmania extrusion and feed production facility. The sale of the facility to Skretting Australia will put $54.85 million into Ridley’s pocket and is expected to be finalised in the first half of FY22. The Company cites

    Read More
    Public
  • My Food Bag revenue increases as hungry Kiwis seek diet variety outside of ‘fush and chups’

    Contrary to popular belief, the Kiwis do not only eat ‘fush and chups’. Just like us Aussies, our neighbours do in fact eat a wide and varied diet not dissimilar to ours. My Food Bag (ASX: MFB) is one company delivering fresh ingredients across New Zealand in the form of meal kits. The Company has

    Read More
    Public
  • IPO Watch: Argenica Therapeutics developing drugs for brain recovery

    Every 19 minutes someone has a stroke. In 2019 that was 13 million people globally. During a stroke, the lack of oxygen caused by the blockage of blood vessels kills 1.9 million brain cells per minute. The medical interventional methods available to stroke patients are limited and focus on removing the clot chemically or mechanically.

    Read More
    Public
  • Applyflow sales rise as one-click apply emerges as the future of recruitment

    Many graduates lament over the old, clunky and annoying recruitment platforms and job boards that they are forced to trawl in the hopes of getting a foot in the door of their chosen industry. It’s no surprise that 60% of applications get abandoned due to complexity. It’s high time that something newer, streamlined and just

    Read More
    Public
  • Mosquitoes suck. Island Pharmaceuticals does not.

    Fun fact: The word mosquito actually translates to “little fly” in Spanish. Although you’re more likely to hear them called a whole host of profanities in many households. Little f***ers. If the blood sucking pests weren’t annoying enough, they carry diseases like dengue fever. An estimated 390 million people are infected with dengue each year.

    Read More
    Public
  • Nutritional Growth Solutions launches new snack bar to grow kids taller

    Ever noticed how the nutritional supplements that line the aisles of supermarkets and pharmacies are either for adults or children under the age of three? What about the kids in the middle? Key development continues well past the age of three and optimal nutrition plays a huge role in reaching developmental milestones. Addressing this long

    Read More
    Public
  • Medtech device sales a key step forward for LBT Innovations

    LBT Innovations (ASX: LBT) has this morning announced the sale of two of their AI pathology instruments. The Adelaide based med tech company is a leader in medical technology automation through the use of artificial intelligence.  Their flagship product is the APAS® Independence. The Automated Plate Assessment System (APAS®) technology integrates AI to automate culture

    Read More
    Public
  • BWX to acquire beauty and wellness online retailer Flora & Fauna

    The clean and natural beauty movement is well and truly mainstream. The rise of conscious consumerism has seen the natural beauty and wellbeing market grow by over 12% annually.  The proliferation of small brands that gain cult following are eroding the market share of the big players.  BWX (ASX: BWX) is a leading wellness business

    Read More
    Public
  • Strategic Elements: Homegrown innovation to quell invisible threats

    The threat of chemical, biological, radiological and nuclear (CBRN) attacks on both military and civilian populations is growing.  As if we didn’t already have enough to worry about. Anxiety riddled, chronic overthinkers and savvy investors alike will be glad to know that Strategic Elements (ASX: SOR) are working on solutions for autonomous sensing and search

    Read More
    Public
  • Lucapa found a 138 carat diamond, Danny Archer jealous

    Diamonds may very well be an investor’s best friend this morning with the Lucapa Diamond Company (ASX: LOM) announcing the finding of the 24th 100+ carat diamond from the Lulo alluvial diamond mine in Angola. The 138 carat stone brings the Company’s tally of 100+ carat diamonds found this year alone to 7. It is

    Read More
    Public
  • Delta Drone expands training operations, targets Namibia

    If you ever needed confirmation that we really are living in the future, all you need to do is look through the ASX listed tech companies and what they’re doing. The scope of our technological capabilities is downright impressive.  One company that might be of interest is Delta Drone International (ASX: DLT), a global Drones-as-a-Service

    Read More
    Public
  • IPO Watch: Australian Clinical Labs to list after successfully raising $408m

    In and amongst the slew of resource based IPOs vying for listing this month is Australian pathology company Australian Clinical Labs (Proposed ASX code: ACL).  The Company is hoping to join the likes of their ASX-listed competitors Sonic Healthcare (ASX: SHL) and Healius (ASX: HLS) later this month with an IPO Offer Price of $4

    Read More
    Public
  • How Incannex is helping you catch some zzz’s

    Unsurprisingly, four out of ten adults experience regular poor sleep. We all know the consequences of a bad night’s rest on our health, performance and mood, as well as the crippling caffeine addiction that develops. *Sips double shot oat milk latte*  People with Obstructive Sleep Apnoea (OSA) have it worse. OSA is characterised by partial

    Read More
    Public
  • Explain Like I’m 5: Trading vs Investing

    If you explore the world of the share market for more than two minutes you’re bound to come across the words “investing” and “trading”. But what is the difference between the two of them and how do you decide which is right for you? Let’s start with the basics. What is trading?  Trading involves frequent

    Read More
    Public
  • Archer Materials are progressing with their chips, not the salt and vinegar kind

    I’m not sure what’s harder- wrapping your head around what Archer Material’s (ASX: AXE) does, or comprehending the value of the market that they are tapping into. A market which currently sits at a whopping USD $400 billion per annum, and is forecast to reach over USD $1 trillion by 2030. Have I got your

    Read More
    Public
  • Noxopharm receives FDA approval for testing of promising cancer treatment

    Jennie Young was one of the first patients to receive Veyonda, Noxopharm’s (ASX: NOX) proprietary drug. Administered on compassionate grounds, her doctors believe that she responded to it positively. She had leiomyosarcoma, a rare cancer that affects smooth muscle tissue. Soft tissue sarcomas like hers have limited treatment options with only 14% responding to chemotherapy. 

    Read More
    Public
  • Top of the class: Rhythm’s latest study results outperform the standard

    Colorectal cancer is the third most commonly occurring cancer in men, and the second in women. Yet every year 130 million people around the world between the ages of 50-74 remain unscreened. Rhythm Biosciences (ASX: RHY) are not complacent with that number and are working on an innovative solution to aid diagnosis of this major

    Read More
    Public
  • This company’s advanced 3D printing product could become industry standard

    From dental devices to jet engines, 3D printing is quickly becoming mainstream. Its use is moving well beyond prototyping and toys, towards industrial applications. Leading the way in the commercialisation of industrial 3D printers is AML3D (ASX: AL3), and their market update today proves that they plan on staying ahead of the game. The Company

    Read More
    Public
  • Will this sporting tech IPO be a Hit?

    Injury is inevitable in both elite and recreational sport. Most cuts, bruises, strains and tears can be remedied in a relatively short time frame with minimal ongoing issues. Traumatic brain injuries are quite the opposite. They can be debilitating, life altering and career ending. Following increased researcher interest and the findings of multiple studies, the

    Read More
    Public
  • Can Medibio’s software redefine mental health diagnostics?

    Mental illness will have an impact on 45% of Australians at some point in their lifetime. While the world is becoming increasingly aware of mental health conditions, little is being done to redefine the diagnostics. Currently, the gold standard in the diagnosis of mental illness is The Diagnostic and Statistical Manual of Mental Disorders (DSM5).

    Read More
    Public
  • Ingenia are not taking a break, so you can

    Australian’s are slowly pulling down their masks to embrace a new normal in the wake of the pandemic. Travel, at least domestically, is returning to pre-covid levels, a welcome change for those working in and around one of the hardest hit industries. Amongst those relieved companies is Ingenia Communities (ASX: INA). The Company is welcoming

    Read More
    Public
  • This company is really neat

    Craft beverage ‘accelerator’ Mighty Craft (ASX: MCL) has been getting Aussies tipsy on beer, spirits and now, whiskey.  The Company has today announced the appointment of two guys to their ‘Whiskey Acceleration Team’ (a trivia night team name winner for sure) whose job it is to get you buzzed.  Chris Malcolm and George Campbell are

    Read More
    Public
  • How three companies are collaborating to tackle an epidemic

    Three companies are joining forces to help tackle one of the most serious public health challenges of our time – the HIV/AIDS epidemic. Viatris and Atomo Diagnostics (ASX: AT1) have announced an agreement with Unitaid to increase accessibility of HIV self-testing in low-and middle-income countries (LMICs).  The announcement represents significant market expansion, with Unitaid committing

    Read More
    Public
  • Do you really own your shares?

    The global pandemic affected almost every aspect of modern life, and the stock market was no exception. The stock market crash early in 2020 saw an influx of retail investors and a huge increase in the number of accounts opened on trading apps. While investing is almost always a positive step towards financial freedom, experts

    Read More
    Public
  • Latitude IPO successful but how big will the exit selldown be?

    The saying ‘third time’s a charm’ rings true for financial services company Latitude (ASX: LFS) who finally made their entrance to the public market last week after cementing themselves as the biggest ASX float of 2021   This year’s offering marked Latitude’s third attempt at an IPO. Their first attempt was stalled in 2018 by investor

    Read More
    Public
  • PharmAust is putting a leash on canine cancer, and COVID-19

    From high rise city apartments to the rolling hills of the countryside, you’re likely to find a dog or two snuggled up on the living room couch. Studies have proven what us dog loving people already know- that the human-canine bond is special. Owning a dog reduces stress, alleviates anxiety and even can prolong your

    Read More
    Public
  • How 4DMedical is changing the medtech game post COVID

    While we are seemingly on the back-stretch of the COVID-19 pandemic, increased medical awareness has changed how we diagnose respiratory diseases with medtech company 4DMedical (ASX: 4DX) leading the charge. Their proprietary FDA/TGA approved, patented respiratory imaging platform, XV Technology turns sequences of x-ray images into four-dimensional, quantitative data to improve and accelerate diagnostic accuracy.

    Read More
    Public
  • High-touch, high-quality maternity care could soon become standard in major hospitals

    Bringing telehealth to expectant mothers that will rival major hospital facilities, medtech company HeraMED (ASX: HMD) is taking a significant step forward in the commercialisation of their foetal monitoring device. As part of their Technology as a Service (TaaS) recurring revenue model, the Company has entered into an agreement with Joondalup Health Campus (JHC) which

    Read More
    Public
  • New Anatara trial to tackle anxiety, stress and depression with diet supplement

    Working in conjunction with the CSIRO, Anatara Lifesciences (ASX: ANR) has received ethics approval to apply their diet supplement 3FDC to a new area of medicine, seeking to evaluate the compound’s effects in adults with moderate anxiety, stress and depression. 3FDC is one of the constituents of Anatara’s flagship supplement (GaRP) intended for the treatment

    Read More
    Public
  • Could Creso’s psychedelics solve Australia’s $10.6 billion problem?

    According to the Australian Department of Health, half of us will experience some form of mental illness in our lifetime. Treatment is somewhat limited to prescription medications and psychotherapy. However, the current mental health crisis has seen researchers and practitioners alike wondering- is there a better way to approach these frighteningly common conditions? Enter psychedelics,

    Read More
    Public
  • Millenials get happy! Alterra is making your smashed avo dreams come true

    Progressing their next-gen 300-hectare avocado project in Western Australia, sustainable agriculture specialist Alterra (ASX:1AG) could soon be extending the live-at-home lives of millenials that continue to prioritise smashed avo cafe breakfasts ahead of financial independence. The Company has released an update today on the progress of their flagship 300-hectare avocado project. The Carpenters Project, located

    Read More
    Public
  • The rising BNPL star giving Afterpay a run for their money

    Zip Co (ASX: Z1P) is nipping at the heels of Australian BNPL leader Afterpay (ASX: APT), based on today’s announcement of their Q3 results. Despite the pandemic, Zip has managed to maintain momentum and deliver strong results across Australian, New Zealand, UK and US markets bolstering itself as one of the fastest growing BNPL leaders.

    Read More
    Public
  • LBT Innovations sets sights on US healthcare market with AI-powered pathology

    Adelaide-based medical technology company LBT Innovations (ASX: LBT) is lining up distributors in the lucrative US healthcare market for their pathology screening tech which is driven by artificial intelligence to maximise testing throughput in labs, providing healthcare professionals with accurate results faster.    The Automated Plate Assessment System (APAS®) is a pathology AI device which automates

    Read More
    Public
  • Encouraging results from Recce Pharmaceuticals in fight against drug resistant bacteria

    As the world prepares for a myriad of drug-resistant bacteria following decades of over-prescribing and improper use of antibiotics, Recce Pharmaceuticals (ASX: RCE) has reported encouraging clinical results in response to multi drug resistant bacterial sinusitis infection. Following on from promising results observed in animal studies, a 59-year-old male was treated with the compound R327

    Read More
    Public